Injectable transplantation system for anticancer in-situ cell therapy
Cancer is the leading cause of death worldwide. Traditional cancer therapy methods include surgery, radiotherapy, chemotherapy, or combinations of them all. In recent years, immunotherapy, as a novel therapeutic method by which the immune system is used to reject specific cancer. In this project...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project |
| Language: | English |
| Published: |
2009
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10356/16682 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Cancer is the leading cause of death worldwide. Traditional cancer therapy
methods include surgery, radiotherapy, chemotherapy, or combinations of them all. In
recent years, immunotherapy, as a novel therapeutic method by which the immune
system is used to reject specific cancer.
In this project, we are aiming to evaluate the feasibility of remodeling
immunosurveillance into the tumor site, with an engineering, more particularly,
functional materials-mediated cell therapeutic strategy by designing an injectable cell
transplantation system for anti-cancer therapy.
The RAW 264.7 cells are encapsulated in dual-layer hydrogel composite which is
in injectable size. Followed by biochemical activation, the construct is able to constantly
release therapeutic agent. In a long observation period, the cells inside the capsule
gradually die in a spontaneous manner, which is regarded as an advantage of
controllability. The expression of a series of cytokines is switched on or up-regulated to
induce the apoptosis of tumor cells. The different cell viability tests including live-dead
assay, apoptosis test and WST-1 assay suggest that the tumor cells which are cocultured
with post 6 hours LPS challenge agarose encapsulated constructs exhibit distinctively
decreased levels of cell viability. |
|---|